Drug Profile
T 487
Alternative Names: AMG-487; CXCR3 antagonists - AmgenLatest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Amgen; ChemoCentryx
- Class Anti-inflammatories; Pyrimidines; Small molecules
- Mechanism of Action Chemokine receptor antagonists; CXCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis; Rheumatoid arthritis
Most Recent Events
- 03 Jun 2005 No development reported - Phase-I for Rheumatoid arthritis (PO)
- 17 Aug 2004 Tularik has been acquired and merged into Amgen
- 12 Dec 2003 Phase-II clinical trials in Psoriasis in Europe (PO)